FDA
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at RBC Capital
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
-
322,913 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

